Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis Impact of Timing of Treatment Initiation

Abstract : Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, fatal, fibrosing lung disease. Pirfenidone and nintedanib are oral antifibrotics with demonstrated efficacy in reducing lung function decline in individuals with IPF, independent of baseline lung function. Intervention with an antifibrotic as early as possible in the disease course might be the most appropriate strategy to preserve lung capacity. However, many physicians are reluctant to initiate antifibrotics at diagnosis, and delay treatment until disease progression is observed. Furthermore, certain countries do not reimburse antifibrotic treatment for individuals with preserved lung function (% predicted forced vital capacity [FVC] > 80%). These post hoc analyses aimed to assess: 1) FVC decline during long-term pirfenidone treatment in RECAP in individuals with IPF categorized by baseline % predicted FVC; and 2) the impact of deferring pirfenidone treatment on annual FVC decline in individuals with IPF during CAPACITY and RECAP.
Complete list of metadatas

Cited literature [12 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02119171
Contributor : Xavier Chard-Hutchinson <>
Submitted on : Thursday, July 18, 2019 - 10:46:53 AM
Last modification on : Thursday, August 22, 2019 - 2:44:01 PM

File

Maher-2019-Pirfenidone Treatme...
Files produced by the author(s)

Identifiers

Citation

Toby M Maher, Lisa H Lancaster, Stéphane Jouneau, Lake Morrison, David J Lederer, et al.. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis Impact of Timing of Treatment Initiation. Annals of the American Thoracic Society, American Thoracic Society, 2019, 16 (7), pp.927-930. ⟨10.1513/AnnalsATS.201810-720RL⟩. ⟨hal-02119171⟩

Share

Metrics

Record views

39

Files downloads

20